D. Western Therapeutics Institute, Inc. (TYO:4576)

Market Cap	5.32B -17.8%
Revenue (ttm)	419.76M -9.4%
Net Income	-1.06B
EPS	-23.85
Shares Out	54.25M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	540,300
Average Volume	447,670
Open	99.00
Previous Close	100.00
Day's Range	97.00 - 100.00
52-Week Range	87.00 - 192.00
Beta	-0.11
RSI	43.97
Earnings Date	Feb 13, 2026

About TYO:4576

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocain...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 21
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4576

Financial Performance

In 2024, TYO:4576's revenue was 471.00 million, an increase of 10.05% compared to the previous year's 428.00 million. Losses were -1.29 billion, 58.9% more than in 2023.